Modality
Vaccine
MOA
BTKi
Target
Aβ
Pathway
T-cell
Endometrial Ca
Development Pipeline
Preclinical
~Sep 2011
→ ~Dec 2012
Phase 1
~Mar 2013
→ ~Jun 2014
Phase 2
~Sep 2014
→ ~Dec 2015
Phase 3
~Mar 2016
→ ~Jun 2017
NDA/BLA
~Sep 2017
→ ~Dec 2018
Approved
Mar 2019
→ Feb 2029
ApprovedCurrent
NCT03535533
958 pts·Endometrial Ca
2019-03→2029-02·Completed
NCT07605100
780 pts·Endometrial Ca
2022-05→2026-02·Completed
1,738 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2026-02-151mo agoPh3 Readout· Endometrial Ca
2029-02-052.9y awayPh3 Readout· Endometrial Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Approved
Complet…
Approved
Complet…
Catalysts
Ph3 Readout
2026-02-15 · 1mo ago
Endometrial Ca
Ph3 Readout
2029-02-05 · 2.9y away
Endometrial Ca
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03535533 | Approved | Endometrial Ca | Completed | 958 | MRD |
| NCT07605100 | Approved | Endometrial Ca | Completed | 780 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 |